Getein Biotech (SHSE:603387) Shares Outstanding (EOP): 507 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:603387 Getein Biotech Inc SHSE:603387
77 GF Score
Price ¥8.90
GF Value ¥7.57
Valuation Modestly Overvalued
! 2 Warning Signs
View Full Analysis

What is Getein Biotech Shares Outstanding (EOP)?

Getein Biotech SHSE:603387 77 Shares Outstanding (EOP) is 507 Mil as of Mar. 2026. GuruFocus rates SHSE:603387 with a GF Score™ of 77/100 and a GF Value™ of ¥7.57 (Modestly Overvalued). The stock has 2 warning signs investors should review.

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Getein Biotech's shares outstanding for the quarter that ended in Mar. 2026 was 507 Mil.

Getein Biotech's quarterly shares outstanding stayed the same from Dec. 2025 (507 Mil) to Mar. 2026 (507 Mil).

Getein Biotech's annual shares outstanding stayed the same from Dec. 2024 (507 Mil) to Dec. 2025 (507 Mil).


Getein Biotech  (SHSE:603387) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Getein Biotech Shares Outstanding (EOP) Related Terms


Getein Biotech Shares Outstanding (EOP) Historical Data

* Premium members only.

The historical data trend for Getein Biotech's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Getein Biotech Shares Outstanding (EOP) Chart

Getein Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Shares Outstanding (EOP)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 509.34 507.15 507.15 507.15 507.15

Getein Biotech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 507.15 507.15 507.15 507.15 507.15

SHSE:603387 vs ABT, SYK, MDT: Shares Outstanding (EOP) Comparison

For the Medical Devices subindustry, Getein Biotech's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Getein Biotech Shares Outstanding (EOP) vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Getein Biotech's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Getein Biotech's Shares Outstanding (EOP) falls into.


SHSE:603387
77GF Score
Getein Biotech Inc SHSE:603387
Shares Outstanding (EOP) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Getein Biotech Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.

What does a Shares Outstanding (EOP) of 507 Mil mean?
Getein Biotech (SHSE:603387) has a Shares Outstanding (EOP) of 507 Mil as of Mar. 2026. The total shares a company has outstanding, at period-end. View historical data on Getein Biotech and its competitors.
Is Getein Biotech's Shares Outstanding (EOP) too high?
Getein Biotech's current Shares Outstanding (EOP) is 507 Mil. Overall, Getein Biotech has a GF Score™ of 77/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Getein Biotech's Shares Outstanding (EOP) compare to ABT and SYK?
Getein Biotech's Shares Outstanding (EOP) of 507 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (EOP) for a Medical Devices & Instruments company?
A good Shares Outstanding (EOP) depends on the Medical Devices & Instruments industry context. However, Shares Outstanding (EOP) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (EOP) mean?
A high Shares Outstanding (EOP) can signal that a stock is expensive relative to its fundamentals. The total shares a company has outstanding, at period-end. View historical data on Getein Biotech and its competitors. Getein Biotech's current Shares Outstanding (EOP) is 507 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Getein Biotech stock overvalued right now?
Based on GuruFocus' analysis, Getein Biotech (SHSE:603387) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥7.57, compared to a current price of ¥8.90 — trading 17.6% above its estimated fair value. The current Shares Outstanding (EOP) is 507 Mil. Getein Biotech's overall GF Score™ is 77/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (EOP) calculated?
Shares Outstanding (EOP) is calculated from a company's financial statements. For Getein Biotech (SHSE:603387), the current Shares Outstanding (EOP) is 507 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Getein Biotech (SHSE:603387) Overvalued in 2026?

Based on GuruFocus' analysis, Getein Biotech stock appears to be overvalued. The current stock price of ¥8.90 is trading 17.6% above its estimated GF Value™ of ¥7.57. GuruFocus considers Getein Biotech to be Modestly Overvalued.

Key valuation signals for SHSE:603387:

  • Shares Outstanding (EOP): 507 Mil
  • GF Value™: ¥7.57 vs. price of ¥8.90 (17.6% above fair value)
  • GF Score™: 77/100 with 2 warning signs

No single metric tells the full story. See the SHSE:603387 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Getein Biotech Business Description

Address No. 9 Bofu Road, Luhe District, Nanjing, CHN, 211505
Getein Biotech Inc is an in-vitro diagnostic company. It is specializing in analytical medical devices and point-of-care testing kits. Its product lines consist of cardiovascular, inflammatory, diabetes, fertility, renal, liver and specialty assays.
77GF Score

Get the complete analysis for SHSE:603387

Shares Outstanding (EOP) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥8.90
Price
¥7.57
GF Value